Video Experimental Relacionado
Updated: May 5, 2026
05:04
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
2.9K
Una vía redox-dependiente para regular los HDAC de clase II y la hipertrofia cardíaca
Tetsuro Ago1, Tong Liu, Peiyong Zhai
1Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ 07103, USA.
Cell
|June 17, 2008
Resumen
La tioredoxina 1 (Trx1) reduce el estrés oxidativo en la hipertrofia cardíaca mediante la modificación de las histonas desacetilasas (HDAC). Esta regulación redox evita la exportación nuclear de HDAC, ofreciendo un nuevo objetivo terapéutico para las enfermedades del corazón.
Área de la Ciencia:
- Biología Molecular Biología Molecular
- Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular Investigación Cardiovascular
- Biología redox Biología redox.
Sus antecedentes:
- La tioredoxina 1 (Trx1) es un regulador clave del equilibrio redox celular, que influye en el crecimiento y muerte celular.
- La hipertrofia cardíaca, un aumento en la masa del músculo cardíaco, es una respuesta inadaptada que a menudo conduce a la insuficiencia cardíaca.
- Las desacetilasas de histona de clase II (HDAC) son reguladores negativos críticos de la hipertrofia cardíaca.
Objetivo del estudio:
- Para dilucidar el mecanismo molecular por el cual Trx1 atenúa la hipertrofia cardíaca.
- Investigar el papel de la modificación redox en la regulación de los HDAC de clase II durante la hipertrofia cardíaca.
Principales métodos:
- Se ha investigado la regulación mediada por Trx1 de DnaJb5 y los HDAC de clase II.
- Se analizó la modificación redox (oxidación y reducción) de residuos específicos de cisteína en DnaJb5 y HDAC4.4.
- Se evaluó el impacto de estas modificaciones en las interacciones proteína-proteína y la localización subcelular (exportación nuclear).
Principales resultados:
- Trx1 aumenta la regulación de DnaJb5 y forma un complejo con DnaJb5 y los HDAC de clase II.
- Trx1 reduce los residuos oxidados de cisteína en DnaJb5 (Cys-274/Cys-276) y HDAC4 (Cys-667/Cys-669) bajo estímulos hipertróficos.
- La reducción de las cisteínas DnaJb5 es crucial para la interacción DnaJb5-HDAC4, mientras que la reducción de las cisteínas HDAC4 inhibe su exportación nuclear.
Conclusiones:
- La hipertrofia cardíaca está regulada por un nuevo mecanismo sensible a Trx1 que implica la modificación redox de los HDAC de clase II.
- La modificación redox de HDAC4 por Trx1 modula su transporte nucleocitoplasmático, lo que afecta la señalización hipertrófica.
- Este estudio revela una estrategia terapéutica potencial dirigida a las vías redox en la hipertrofia cardíaca.
Videos de Conceptos Relacionados
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:17Pathophysiology of Heart Failure
4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
805
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
01:27Redox Reactions
1.2K
Redox reactions are vital biochemical processes that underpin energy metabolism in cells. These reactions involve the transfer of electrons between molecules, occurring in tandem as oxidation and reduction. Oxidation refers to the loss of electrons, while reduction denotes their gain. This coupling ensures the seamless flow of electrons through metabolic pathways. For example, in bacterial metabolism, glucose undergoes oxidation to carbon dioxide, while oxygen is simultaneously reduced to...
1.2K
01:26Cellular Adaptation II: Hypertrophy
54
Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
54